Pall Corporation announced today that it has acquired the BioSMB technology platform from Tarpon Biosystems. The addition of Tarpon’s cutting-edge technology with Pall’s engineering capabilities and innovative single use technologies will accelerate the adoption of continuous downstream processing into biopharmaceutical manufacturing.
The BioSMB chromatographic systems enable single use, multi-column chromatography for process development and are well placed for multi-product and single use facilities. The addition of the BioSMB technology expands Pall’s portfolio in continuous processing technology at both the process development and GMP scales of operation, while complementing the Allegro™ products and single-use systems portfolio.
More information